Seer, INC 8-K filings

Seer, Inc. announced second quarter 2026 financial results, reporting $3.1 million in revenue, a 23% decrease year-over-year, and a net loss of $16.9 million, while reaffirming full-year revenue guidance.

Seer's CEO, Omid Farokhzad, M.D., has submitted an unsolicited, non-binding proposal to acquire the company for $2.45 per share in cash plus two contingent value rights.

Seer, Inc. confirms receipt of two revised, unsolicited acquisition proposals, one from the Radoff-JEC Group for $2.55 per share and another from CEO Omid Farokhzad for $2.45 per share plus contingent value rights.

Seer, Inc.'s Special Committee unanimously rejected an unsolicited acquisition proposal from CEO Omid Farokhzad, M.D., citing undervaluation and insufficient consideration for long-term growth prospects.

Seer, Inc. announces receipt of an unsolicited, non-binding acquisition proposal from its CEO, Omid Farokhzad, M.D., to take the company private for $2.45 per share in cash plus two contingent value rights.

Seer, Inc. has unanimously rejected a revised unsolicited acquisition proposal from the Radoff-JEC Group, citing significant undervaluation.

Seer, Inc. announced first quarter 2026 financial results, reporting $2.8 million in revenue, a 34% decrease year-over-year, while reaffirming its full-year revenue outlook.

Seer, Inc. announced the appointment of Anthony Bazarko as Chief Commercial Officer to drive growth and adoption of its Proteograph Product Suite.

Seer's Board of Directors has unanimously rejected an unsolicited acquisition proposal from the Radoff-JEC Group, citing significant undervaluation.

Seer, Inc. has confirmed receipt of a non-binding acquisition proposal from Radoff-JEC Group and has been presented with director candidate nominations.

Seer reports a PTAB decision that upholds five of eleven challenged claims and leaves 23 of 29 total claims valid on its Proteograph-related patent, with appeals due by May 25, 2026.

Seer, Inc. amended its Tax Benefit Preservation Plan and paid $250,000 to settle a stockholder lawsuit challenging the plan's beneficial ownership definition.

Seer, Inc. has adopted a Tax Benefit Preservation Plan to safeguard its substantial net operating losses and other tax attributes from potential impairment due to ownership changes.

Seer, Inc. announced its fourth quarter and full year 2025 financial results, reporting increased revenue and a reduced net loss, alongside a 2026 revenue outlook.

Seer, Inc. announced the automatic conversion of all outstanding Class B Common Stock into Class A Common Stock, consolidating voting power to one vote per share.

Seer, Inc. announced its third quarter 2025 financial results, reporting a 2% revenue increase to $4.1 million and a reduced net loss of $18.2 million, alongside strong instrument shipments and a robust cash position.

Seer, Inc. announced the appointment of Isaac Ro, a seasoned financial and life science expert, to its Board of Directors and Audit Committee, addressing potential Nasdaq compliance issues.

Seer, Inc. announced second quarter 2025 financial results, reporting 32% revenue growth and the launch of new high-throughput Proteograph ONE assay and SP200 automation instrument.

Seer, Inc. announced it will no longer comply with Nasdaq's Audit Committee composition rule after its 2025 Annual Meeting but plans to utilize a cure period to regain compliance, while also confirming the election of directors and ratification of its independent auditor.

Seer, Inc. announced a 37% increase in revenue for the first quarter of 2025, driven by higher product and service sales, and reiterated its full-year revenue guidance.

Seer Inc. announces its Q4 and full year 2024 financial results, highlighting revenue, instrument shipments, and a positive outlook for 2025.

Seer Inc. announced its third quarter 2024 financial results, including a new co-marketing agreement with Thermo Fisher Scientific and a revenue of $4.0 million.

Seer, Inc. has repriced underwater stock options for employees and appointed Dr. Nicolas Roelofs to its Board of Directors.

Seer, Inc. has appointed Nicolas Roelofs, Ph.D. to its Board of Directors, naming him Lead Independent Director and granting him stock options and restricted stock units.

Seer Inc. announced its second quarter 2024 financial results, including a revenue of $3.1 million and the launch of its Seer Technology Access Center (STAC) in Europe.

Seer Inc. reports the resignation of its Chief Legal Officer and a board member, along with the appointment of a new audit committee member to maintain Nasdaq compliance.

Seer Inc. reports the resignation of a board member, leading to a temporary non-compliance with Nasdaq listing rules regarding the Audit Committee composition.

Seer, Inc. held its 2024 Annual Meeting of Stockholders, electing four directors and ratifying Deloitte & Touche LLP as its independent auditor for the fiscal year ending December 31, 2024.

Seer Inc. announced a 24% decrease in revenue for Q1 2024 compared to the previous year, alongside the expansion of its technology access program into Europe and a share repurchase program.

Seer Inc. announced its fourth quarter and full year 2023 financial results, showing a slight decrease in Q4 revenue but an overall increase for the year, along with a positive outlook for 2024.